By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Shire LLC v.
Neos Therapeutics, Inc.
3:13-cv-01452;
filed April 11, 2013 in the Northern District of Texas

Infringement
of U.S. Patent Nos. RE42,096 ("Oral Pulsed Dose Drug Delivery
System," issued February 1, 2011) and RE41,148 (same title, issued
February 23, 2010) following a Paragraph IV certification as part of Neos
filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to
manufacture a generic version of Shire's Adderall XR® (a combination of
dextroamphetamine saccharate, amphetamine aspartate monohydrate,
dextroamphetamine sulfate, and amphetamine sulfate, used to treat attention
deficit hyperactivity disorder).  View
the complaint here.

Japanese
Foundation for Cancer Research v. Rea et al.
1:13-cv-00412;
filed April 1, 2013 in the Eastern District of Virginia

• Plaintiff: 
Japanese Foundation for Cancer Research
• Defendants: 
Teresa Stanek Rea; United States Patent and Trademark Office

Judicial
review of the USPTO's refusal to grant a petition for withdrawal of an
unauthorized disclaimer of the remaining term of U.S. Patent No. 6,194,187 ("Apoptosis-inducing
Protein and Gene Encoding the Same," issued February 27, 2001).  View the complaint here.